David Vossler, MD, FAAN, and Medical Director of Valley’s Neuroscience Institute is co-author and researcher on two recent papers published in Epilepsia, the Official Journal of the International League Against Epilepsy.
The study’s objective was to evaluate the seizure-reduction response and safety of brain-responsive stimulation in adults with medically intractable partial-onset seizures of neocortical origin.
Key points of the study:
- Responsive stimulation is a well-tolerated treatment option for patients with onsets in neocortical areas, including eloquent cortex
- Median seizure reductions were 50 percent using a last observation carried forward (LOCF) analysis
- Twenty-six percent of patients experienced at least one seizure-free period ≥ six months and 14 percent experienced at least one seizure-free period ≥ one year.
The study’s objective was to evaluate the seizure reduction response and safety of mesial temporal lobe (MTL) brain responsive stimulation in adults with medically intractable partial-onset seizures of mesial lobe origin.
Key points of the study:
- Responsive stimulation is a well-tolerated treatment option for patients with mesial temporal lobe epilepsy (MTLE) who are not candidates for a temporal lobe resection
- Median seizure reductions were 70 percent using a last observation carried forward analysis
- Twenty-nine percent of patients reported periods of seizure freedom lasting ≥ 6 months and 15 percent reported seizure-free periods ≥ one year
- Seizure reductions were not dependent on any clinical characteristics including mesial temporal sclerosis (MTS), bilateral onsets, prior resection, and prior vagus nerve stimulation (VNS)
- Seizure reductions were similar in patients with depth leads placed within or adjacent to the hippocampus
